NSPR News and Press, InspireMD Inc. From 11/08/22

InspireMD, Inc. (NSPR) Q3 2022 Earnings Conference Call November 8, 2022 08:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partner...

- Generated 38.8% growth in CGuard™ revenue year-over-year - - Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 - - Announced strategic pa...

InspireMD press release ( NASDAQ: NSPR ): Q3 GAAP EPS of -$0.58 beats by $0.15 . Revenue of $1.43M (+33.6% Y/Y) beats by $0.03M . Cash and cash equivalents of $3.93M as at Sep.30. For further details see: InspireMD GAAP EPS of -$0.58 beats by $0.15, r...

TEL AVIV, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2022 financial res...

TEL AVIV, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver a presentation at the 2022 Transcatheter Cardiovascular Therapeuti...

NAMSA , a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc . (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of st...

InspireMD, Inc. (NSPR) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Chuck Padala - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Benjam...

InspireMD press release ( NASDAQ: NSPR ): Q2 GAAP EPS of -$0.59 beats by $0.14 . Revenue of $1.53M (+48.5% Y/Y) beats by $0.33M . For further details see: InspireMD GAAP EPS of -$0.59 beats by $0.14, revenue of $1.53M beats by $0.33M

- Generated 47.8% growth in CGuard™ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission - - Announced that endovascular pioneer Dr. Juan Parodi has agreed...

InspireMD ( NASDAQ: NSPR ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.73 (-58.7% Y/Y) and the consensus Revenue Estimate is $1.2M (+16.5% Y/Y). Over the last 3 months, EPS estimates have se...